WBC
PYXS icon

West Branch Capital’s Pyxis Oncology PYXS Stock Holding History

West Branch Capital’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25
Closed -$107 – 433
2024
Q1 		$107 Hold
25
– – ﹤0.01% 418
2023
Q4 		$45 Hold
25
– – ﹤0.01% 441
2023
Q3 		$50 Hold
25
– – ﹤0.01% 439
2023
Q2 		$64 Hold
25
– – ﹤0.01% 446
2023
Q1 		$101 Buy
+25
New +$50 ﹤0.01% 452

Other funds holding PYXS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

West Branch Capital's PYXS Position: Q2 2024 in Review

West Branch Capital sold out of Pyxis Oncology (PYXS) in Q2 2024, closing a stake of 25 shares — an estimated $107 sold.

West Branch Capital first reported a position in PYXS in Q1 2023 and held it in 5 quarters. The position peaked at $107 in Q1 2024. 80 funds tracked by Wall St. Rank hold PYXS as of Q2 2024.

  • West Branch Capital reported no remaining Pyxis Oncology position as of Q2 2024 after selling out during the quarter.
  • West Branch Capital sold 25 Pyxis Oncology shares in Q2 2024, an estimated $107.
  • West Branch Capital first reported a position in Pyxis Oncology in Q1 2023 and held it in 5 quarters.
  • West Branch Capital's Pyxis Oncology position peaked at $107 in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2024.

Based on West Branch Capital's 13F filing for Q2 2024, filed 26 Jul 2024.